Overview
Chromosome Y microdeletion syndrome, also known as Y chromosome microdeletion or AZF (azoospermia factor) microdeletion, is a genetic condition caused by the loss of small segments of DNA on the Y chromosome. These microdeletions primarily affect the long arm of the Y chromosome (Yq11) in regions known as AZFa, AZFb, and AZFc, which contain genes critical for normal sperm production (spermatogenesis). The condition is one of the most common known genetic causes of male infertility. The primary body system affected is the male reproductive system. Men with Y chromosome microdeletions typically present with severely impaired sperm production, ranging from oligozoospermia (very low sperm count) to complete azoospermia (absence of sperm in the ejaculate). The severity of the condition depends on which AZF region is deleted: AZFa deletions generally result in Sertoli cell-only syndrome with complete absence of germ cells; AZFb deletions typically cause maturation arrest of spermatogenesis; and AZFc deletions, which are the most common, are associated with a variable phenotype ranging from oligozoospermia to azoospermia. Physical examination is often normal, and the condition is usually discovered during evaluation for infertility. Testicular size may be reduced in some cases. There is no curative treatment for Y chromosome microdeletion syndrome. However, assisted reproductive technologies (ART), particularly intracytoplasmic sperm injection (ICSI), can help affected men achieve biological fatherhood when residual sperm can be retrieved from the ejaculate or through testicular sperm extraction (TESE). Men with AZFc deletions have the best prognosis for successful sperm retrieval, while those with complete AZFa or AZFb deletions rarely have retrievable sperm. Genetic counseling is essential, as male offspring conceived through ART will inherit the Y chromosome microdeletion and will likely also experience fertility problems.
Also known as:
Clinical phenotype terms— hover any for plain English:
Variable
Can be inherited in different ways depending on the underlying gene
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
1 eventMoctanin: FDA approved
For dissolution of cholesterol gallstones retained in the common bile duct.
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Chromosome Y microdeletion syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Chromosome Y microdeletion syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Chromosome Y microdeletion syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
1 resourcesMoctanin
Ethitek Pharmaceuticals, Inc.
Travel Grants
No travel grants are currently matched to Chromosome Y microdeletion syndrome.
Community
No community posts yet. Be the first to share your experience with Chromosome Y microdeletion syndrome.
Start the conversation →Latest news about Chromosome Y microdeletion syndrome
No recent news articles for Chromosome Y microdeletion syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Chromosome Y microdeletion syndrome
What is Chromosome Y microdeletion syndrome?
Chromosome Y microdeletion syndrome, also known as Y chromosome microdeletion or AZF (azoospermia factor) microdeletion, is a genetic condition caused by the loss of small segments of DNA on the Y chromosome. These microdeletions primarily affect the long arm of the Y chromosome (Yq11) in regions known as AZFa, AZFb, and AZFc, which contain genes critical for normal sperm production (spermatogenesis). The condition is one of the most common known genetic causes of male infertility. The primary body system affected is the male reproductive system. Men with Y chromosome microdeletions typically
At what age does Chromosome Y microdeletion syndrome typically begin?
Typical onset of Chromosome Y microdeletion syndrome is adult. Age of onset can vary across affected individuals.
What treatment and support options exist for Chromosome Y microdeletion syndrome?
1 patient support program are currently tracked on UniteRare for Chromosome Y microdeletion syndrome. See the treatments and support programs sections for copay assistance, eligibility, and contact details.